NF-κB, SUMO ve Ubikitinasyon İlişkisi
NF-κB, DNA’ya doğrudan bağlanarak genlerin ekspresyonunu düzenleyen bir transkripsiyon faktörüdür.İmmünitede, hücre sağkalımında, hücre çoğalmasında, öğrenme ve bellek süreçlerinde görevlidir.Post-translasyonel modifikasyonda görevli olan SUMO proteini eksprese edilen proteinlerin fonksiyonlarınıdüzenler ve memelilerde dört adet homoloğu bulunmaktadır.Bir diğer posttranslasyonel modifikasyonda görevli olan protein ise ubikitindir. Birçok biyolojik yolaktayer alır ve işaretlediği proteinleri proteozom sistemine yönlendirerek yıkımını sağlar.Bu derlemede NF-κB, SUMO ve ubikitin proteinlerinden ve birbirleriyle olan ilişkilerinden bahsedilecektir.
NF-κB, SUMO and Ubiquitination Relationship
NF-κB is a transcription factor that regulates the expression of genes by directly binding to DNA.It’s involved in immune system, cell survival, cell proliferation, learning and memory processes.The SUMO protein, which is involved in post-translational modification, regulates the function ofexogenous proteins and there are four homologs in mammals.Another protein involved in post-translational modification is ubiquitin. It is involved in many biologicalpathways and leads the marked proteins to destruction by directing them to the proteosomesystem.In this review NF-κB, SUSMO and ubiquitin proteins and their relationship to each other will bediscussed.
___
- 1. Schmitz ML, Mattioli I, Buss H, Kracht M. NF-
κB: A multifaceted transcription factor regulated
at several levels. Chem Bio Chem
2004; 5: 1348-1358.
2. Sen R, Baltimore D. Multiple nuclear factors
interact with the immunglobulin enhancer
sequences. Cell 1988; 46: 705- 716.
3. Zhang L, Badgwell DB, Bevers JJ, Schlessinger
K, Murray PJ, Levy DE, Watowich SS. IL-6
signaling via the STAT3/SOCS3 pathways:
Functional analysis of the conserved STAT3
N-domain. Mol Cell Biochem 2006; 288 (1-
2): 179-189.
4. Sun XF, Zhang H. NFKB and NFKBI polymorphisms
in relation to susceptibility of
tumour and other diseases. Histol
Histopathol 2007; 22: 1387-1398.
5. Dalmızrak A, Kosova B. TANK proteininin sinyal
iletimindeki fonksiyonel analizi. Yüksek
Lisans Tezi, İzmir 2005.
6. Ekinci Ö, Memis L. Küçük hücreli dışı akciğer
karsinomlarında nükleer faktör kappa B immünohistokimyasal
ekspresyonunun prognozla
ilişkisi. Gazi Tıp Dergisi 2008; 19 (1):
1-5.
7. Camandola S, Mattson MP. NF-κB as a therapeutic
target in neurodegenerative diseases.
Expert Opin Ther Targets 2007; 11 (2):
123-131.
8. Calzado MA, Bacher S, Schmitz ML. NF- ĸB inhibitors
for the treatment of inflammatory
diseases and cancer. Curr Med Chem 2007;
14: 367-376.
9. Hoffman A, Baltimore D. Circuitry of nuclear
factor κB signalling. Immunol Rev 2006;
210: 171-186.
10. Ling L, Cao Z, Goeddel DV. NF-kappaB-inducing
kinase activates IKKalpha by
phosphorylation of Ser-176. Proc Natl Acad
Sci USA 1998; 95: 3792-3797.
11. Lindström TM, Bennett PR. The role of nuclear
factor kappa B in human labour.
Reprodu-ction 2005; 130: 569-581.
12. Yamamoto Y, Gaynor RB. Therapeutic potential
of inhibition of the NF- κB pathway in the
treatment of inflammation and cancer. The
J Clin Invest 2001; 107 (2): 135-142.
13. Umezawa K. Inhibition of tumor growth by
NF-κB inhibitors. Cancer Sci 2006; 97 (10):
990- 995
14. Melchior F, Schergaut M, Pichler A. SUMO:
ligases, isopeptidases and nuclear pores.
Trends in Biochemic Sci 2003; 28: 612-618.
15. Melchior F. SUMO – nonlassical ubiquitin.
Annu Rev Cell Dev Biol 2000; 16: 591-626.
16. Kamitani T, Kito K, Nguyen HP, Fukuda-Kamitani
T, Yeh ET. Characterization of a second
member of the sentrin family of ubiquitin-like
proteins. J Biol Chem 1998; 273 (18):
11349-11353.
17. Saitoh H, Hinchey J. Functional Heterogeneity
of small ubiquitin-related protein modifiers
SUMO-1 versus SUMO-2/3. J Biol
Chem 2000; 275: 6252-6258.
18. Kolli N, Mikolajczyk J, Drag M, Mukhopadhyay
D, Moffatt N, Dasso M, Salvesen G,
Wilkinson KD. Distribution and parlogue
specificity of mammalian deSUMOylating
enzymes. Biochem J 2010; 430: 335-344.
19. Ayaydin F, Dasso M. Distinct in vivo dynamics
of vertebrate SUMO paralogues. Mol Biol
Cell 2004; 15: 5208-5218.
20. Tatham MH, Jaffray E, Vaughan OA, Desterro
JMP, Botting CH, Naismith JH, Hay RT. Polymeric
Chains of SUMO-2 and SUMO-3 are
conjugated to protein substrates by SAE1/
SAE2 and Ubc9. J Bio Chem 2001; 276 (38):
35368-35374.
21. Matic I, van Hagen M, Schimmel J, Macek
B, Ogg SC, Tatham MH, Hay RT, Lamond
AI, Mann M, Vertegaal ACO. In vivo identification
of human small ubiquitin-like modifier
polymerization sites by high accuracy mass
spectometry and an in vitro to in vivo strategy.
Moll Cell Preotomics 2008; 7: 132-144.
22. Rodriguez MS, Desterro JM, Lain S, Midgley
CA, Lane DP, Hay RT. SUMO-1 modification
activates the transcriptional response of
p53. EMBO J 1999; 15: 6455-6461.
23. Bohren KM, Nadkarni V, Song JH, Gabby KH,
Owerbach D. A M55V polymorphism in a
novel SUMO gene (SUMO-4) differentially
activates heat schock transcirption factors
and is associated with susceptibility to type
I diabetes mellitus. J Biol Chem 2004; 279:
27233-27238.
24. Martin S, Wilkinson KA, Nishimune A, Henly
JM. Emerging exracellular roles of protein
SUMOylation in neuronal function and dysfunction.
Nat Rev Neurosci 2007; 8 (12):
948-959.
25. Song J, Durrin LK, Wilkinson TA, Krontiris TG,
Chen Y. Identification of a SUMO-binding
motif that recognizes SUMO-modified proteins.
Proc Natl Acad Sci 2004; 101: 14373-
14378.
26. Hayashi T, Seki M, Maeda D, Wang W, Kawabe
Y, Seki T, Saitoh H, Fukugawa T, Yagi H,
Enomoto T. Ubc9 is essential for viability of
higher eukaryotic cells. Exp Cell Res 2002;
280 (2): 212-221.
27. Wilkinson KA, Nakamura Y, Henley JM. Targets
and consequences of protein SUMOylation
in neurons. Brain Res Rev 2010; 64
(1); 195-212.
28. Wilkinson KA, Henley JM. Mechanisms, regulation
and consequences of protein SUMOylation
Biochem J 2012; 428 (2): 133-145.
29. Gong L, Li B, Millas S, Yeh ET. Molecular cloning
and characterization of human AOS1
and UBA2, cmponents of the sentrin-activating
enzyme complex. FEBS Lett 1999;
448: 185-189.
30. Johnson ES, Blobel G. Ubc9p is the conjugating
enzyme for the ubiquitin-like protein
Smtp3. J Biol Chem 1997; 272: 26799-26802.
31. Hershko A, Ciechanover A. The ubiquitin system.
Annu Rev Biochem 1998; 67, 425-479.
32. Varshavsky A. The early history of the ubiquitin
field. Protein Sci 2006; 15 (3): 647-654.
33. Clague MJ, Heride C, Urbe S. The demographics
of the ubiquitin system. Trends Cell Biol
2015; 25: 417-426.
34. Komander D, Rape M. The ubiquitin code.
Annu Rev Biochem 2012; 81: 203-229.
35. Ikeda F, Dikic I. Atypical ubiquitin chains: new
molecular signals. Protein modifications:
beyond the usual suspects’ review series.
EMBO Rep 2008; 9: 536 – 542
36. Swatek KN, Komander D. Ubiquitin modifications,
Cell Res 2016; 26: 399–422.
37. Husnjak K, Dikic I. Ubiquitin-binding proteins:
decoders of ubiquitin-mediated cellular
functions. Annu Rev Biochem 2012; 81:
291-322.
38. Hurley JH, Lee S, Prag G. Ubiquitin-binding
domains. Biochem J 2006; 399:361-372.
39. Sun Y. Targeting E3 ubiquitin ligases for cancer
therapy. Cancer Biol Ther 2003; 2
(6): 623-629.
40. Finley D. Recognition and processing of
ubiquitin-protein conjugates by the proteasome.
Annu Rev Biochem 2009; 78: 477-513.
41. Smith DM, Chang SC, Park S, Finley D, Cheng
Y, Goldberg AL. Docking of the proteasomal
ATPases’ carboxyl termini in the 20S proteasome’s
alpha ring opens the gate for
subst-rate entry. Mol Cell 2007; 27 (5):
731-744.
42. Ciechanovera A, Schwartzb AL. The ubiquitin
system: pathogenesis of human diseases
and drug targeting. Biochimica et Biophysica
Acta (BBA) 2004; 1695: 3-17.
43. Chen J, Chen JZ. Regulation of NF-κB by
Ubiquitination. Curr Opin Immunol 2013; 25
(1): 4-12.
44. Skaug B, Jiang X, Chen ZJ. The role of ubiquitin
in NF-kappaB regulatory pathways.
Annu Rev Biochem 2009; 78: 769-796.
45. Karin M, Ben-Neriah Y. Phosphorylation meets
ubiquitination: the control of NFkB activity.
Annu Rev Immunol 2000; 18: 621-663.
46. Etzioni A, Ciechanover A, Pikarsky E. Immune
defects caused by mutations in the ubiquitin
system. J Allergy Clin Immunol 2017; 139:
743-753.
47. Wu CJ, Conze DB, Li T, Srinivasula SM, Ashwell
JD. Sensing of Lys 63-linked polyubiquitination
by NEMO is a key event in
NF-kappaB activation. Nat Cell Biol 2006;
8: 398-406.
48. Ea CK, Deng L, Xia ZP, Pineda G, Chen ZJ.
Activation of IKK by TNFalpha requires site-
specific ubiquitination of RIP1 and polyubiquitin
binding by NEMO. Mol Cell 2006;
22: 245-257.
49. Terzic J, Dikic I. Interplay between ubiquitin
networks and NF-κB signaling. Period Biol
2011; 113 (1): 1-6.
50. Desterro JM, Rodriguez MS, Hay RT. SUMO-
1 modification of IkappaBalpha inhibits
NF-kappa-B activation. Mol Cell 1998; 2:
233-239.
51. Hayden MS, Ghosh S. Signalling to NF-kappaB.
Genes Dev 2004; 18: 2195-2224.
52. Chen Z, Hagler J, Palombella VJ, Melandri F,
Scherer D, Ballard D, Maniatis T. Signal-induced
site-specific phosphorylation target I
kappa B alpha to the ubiquitin-proteasome
pathway. Genes Dev 1995; 9: 1586-1697.
53. Magnani M, Crinelli R, Bianchi M, Antonelli A.
The ubiquitin-dependent proteolytic system
and other potential targets for the modulation
of nuclear factor-ĸb (NF-ĸb). Curr
Drug Targets 2000; 1: 387-399.
54. Wilson WG. SUMO regulation of cellular processes,
advances in experimental medicine
and biology. Springer, Berlin, Germany, 2nd
ed. 2017; pp 1-12.
55. Chen A, Mannen H, Li SS. Characterization
of mouse ubiquitin-like SMT3A and SMT3B
cDNAs and gene/pseudogenes. Biochem
Mol Biol Int 1998; 46: 1161-1174.
56. Bayer P, Arndt A, Metzger S, Mahajan R, Melchior
F, Jaenicke R, Becker J. Structure determination
of the small ubiquitin-related
modifier SUMO-1. J Mol Biol 1998; 280:
275-286.
57. Lois LM, Lima CD. Structures of the SUMO
E1 provide mechanistic insights into SUMO
activation and E2 recruitment to E1. EMBO
J 2005; 24: 439-451.
58. Deshaies RJ, Joazeiro CA. RING domain E3
ubiquitin ligases. Annu Rev Biochem 2009;
78: 399-434.
59. Gareau JR, Lima CD. The SUMO pathway:
Emerging mechanisms that shape specificity,
conjugation and recognition. Nat Rev
Mol Cell Biol 2010; 11: 861-871.
60. Escobar-Ramirez A, Vercoutter-Edouart AS,
Mortuaire M, Huvent I, Hardivillé S, Hoedt
E, Lefebvre T, Pierce A. Modification by SUMOylation
Controls Both the Transcriptional
Activity and the Stability of Delta-Lactoferrin.
PloS one, DOI:10.1371/journal.
pone.0129965, Jun 15, 2015.
61. Klenk C, Humrich J, Quitterer U, Lohse MJ.
SUMO-1 controls the protein stability and
the biological function of phosducin. J Biol
Chem 2006; 281: 8357-8364.
62. Jackson SP, Durocher D. Regulation of DNA
damage responses by ubiquitin and SUMO.
Mol Cell 2013; 49: 795-807.
63. Nie M, Aslanian A, Prudden J, Heideker J,
Vashisht AA, Wohlschlegel JA, Yates JR,
Boddy MN. Dual recruitment of Cdc48 (p97)-
Ufd1-Npl4 ubiquitin-selective segregase by
small ubiquitin-like modifier protein (SUMO)
and ubiquitin in SUMO-targeted ubiquitin ligase-
mediated genome stability functions.
J Biol Chem 2012; 287 (35): 29610-29619.
64. Ulrich HD. Ubiquitin and SUMO in DNA repair
at a glance. J Cell Sci 2012; 125: 249-254